NCT04278820View on ClinicalTrials.gov

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

PHASE2UnknownINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Primary Biliary Cirrhosis
Interventions
DRUG

TQA3526

Tablet(s) administered orally once daily

DRUG

Placebo to match TQA3526

Tablet(s) administered orally once daily

Trial Locations (1)

130000

The first hospital of Jilin University, Changchun

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY